• IP And Technology Transfer

WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers

WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies

Accelerate@Babraham Start-up Programme underway with four new life science start-ups taking part in the five month programme

Benefits of the programme include access to the Babraham Research Campus bio-incubator facilities, an extended programme of mentoring and support and £10k undiluted funding

CombiGene and CGT Catapult collaboration completes development of quality control analytical assays for clinical production of CombiGene’s AAV-based gene therapy for the treatment of epilepsy

The extensive and advanced work to develop the critical analytical assays needed for quality control in the manufacture of the AAV1 based gene therapy product CG01 has now been completed in a collaboration between CombiGene and CGT Catapult. CombiGene will now integrate the analytical assays into its production process, taking it another step closer to its final large scale production design for clinical trials and commercial distribution.

CGT Catapult Annual Review 2020 highlights impact on growth and productivity in the UK cell and gene therapy industry

The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies.

Eisai pledges its support for the Babraham Research Campus’ Accelerate@Babraham initiative; supporting early-stage science and new life science companies within the cluster

The Babraham Research Campus is delighted to confirm Eisai as the latest high-profile organisation to provide financial and mentoring support for its Accelerate@Babraham initiative. Eisai join AstraZeneca, LifeArc and Mundipharma in providing funding towards the continued development of the bio-incubator programme

Fieldfisher Life Sciences sector group mobilises to offer pro bono legal advice for COVID-19

Fieldfisher are delighted to announce that their pan-European Life Sciences sector group have mobilised to show support for life science companies contributing efforts towards global pandemic COVID-19.

UCL supports worldwide dissemination of free-to-access manufacturing instructions for COVID-19 breathing aids

Governments across the world, healthcare providers and device manufacturers can now request a free of charge licence to the design and manufacturing files of a breathing aid developed by UCL, UCLH and Mercedes-AMG High Performance Powertrains (Mercedes-AMG HPP) to support healthcare systems preparing for the Covid-19 pandemic.

ERS Genomics announces agreement with New England Biolabs to commercialize CRISPR gene editing tools and reagents

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with New England Biolabs (NEB®), a global leader in the discovery and production of enzymes for molecular biology applications, granting NEB rights to sell CRISPR/Cas9 tools and reagents.

Guest blog | Sean Morgan-Jones | UK Biotech PLC is Totally Smashing It...

‘The UK is leading a two speed Europe’ (McKinsey & Company, Biotech in Europe: Scaling Innovation May 20, 2019). One of the key findings and contrary to the received wisdom, is that the UK is totally smashing it on all measures as a Biotech hot spot according to research presented at BioEquity Europe in Barcelona by McKinsey & Company looking at where's hot and where's not. Of the 1,000 European Biotechs established since 2012 the UK is leading by a country mile and represents 35% of all new Biotechs and according to the report and is leading a two speed Europe (with Germany, France and Spain in relative decline). 

BIA blog | CJEU decision denies SPCs for new formulations

The latest decision concerning Supplementary Protection Certificates (SPCs) was handed down by the CJEU in the Abraxis Bioscience case (C-443/17) on 21 March. The BIA’s IP Advisory Committee (IPAC) provided informal views on behalf of the sector to the UK Intellectual Protection Office (IPO) regarding this case, to inform the UK Government’s representations to the CJEU. Andrew Hutchinson of Simmons & Simmons and a member of IPAC has provided the following analysis for BIA members.